We have located links that may give you full text access.
Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Nephrology, Dialysis, Transplantation 2023 January 21
BACKGROUND: The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been concluded, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has increased after introduction of the drug. This study compared the incidence and risk factors of acute kidney injury (AKI) and TLS in patients with MM after bortezomib-based chemotherapy to investigate drug-related nephrotoxicity.
METHODS: From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital. Laboratory TLS was defined according to the Cairo-Bishop definition. Development of AKI was assessed by AKI Network criteria within 7 days of the first chemotherapy.
RESULTS: The median age was 65 [56-72] years, and baseline estimated glomerular filtration rate (eGFR) was 61.3 [34.1-89.1] mL/min/1.73 m2. The incidences of AKI and laboratory TLS were 17% (n = 47) and 13% (n = 36), respectively. Ten (3.6%) subjects met both AKI and TLS criteria. Multivariate analyses showed that lower eGFR category (30∼59, odds ratio [OR] = 3.005 [1.163-7.976]; 15∼29, OR = 4.225 [1.183-15.000]; <15, OR = 16.154 [3.831-70.920] vs ≥ 60, p < 0.001), lower serum albumin level (per 1 increase, OR = 0.479 [0.256-0.871], p = 0.018), renal amyloidosis (OR = 13.039 [4.108-44.041], p < 0.001), and use of acyclovir during bortezomib treatment (OR = 3.689 [1.133-14.469], p = 0.042) were predictors of AKI. MM stages and β-2-microglobulin were not associated with increased risk of AKI. Regarding laboratory TLS, MM stage and β-2-microglobulin were higher in those with TLS than in others. In multivariate analyses, β-2-microglobulin level (OR = 1.204 [1.005-1.461], p = 0.038) and absence of high-risk chromosome abnormalities (OR = 0.143 [0.022-0.588], p = 0.016) were associated with higher risk of TLS.
CONCLUSIONS: Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors of AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function.
METHODS: From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital. Laboratory TLS was defined according to the Cairo-Bishop definition. Development of AKI was assessed by AKI Network criteria within 7 days of the first chemotherapy.
RESULTS: The median age was 65 [56-72] years, and baseline estimated glomerular filtration rate (eGFR) was 61.3 [34.1-89.1] mL/min/1.73 m2. The incidences of AKI and laboratory TLS were 17% (n = 47) and 13% (n = 36), respectively. Ten (3.6%) subjects met both AKI and TLS criteria. Multivariate analyses showed that lower eGFR category (30∼59, odds ratio [OR] = 3.005 [1.163-7.976]; 15∼29, OR = 4.225 [1.183-15.000]; <15, OR = 16.154 [3.831-70.920] vs ≥ 60, p < 0.001), lower serum albumin level (per 1 increase, OR = 0.479 [0.256-0.871], p = 0.018), renal amyloidosis (OR = 13.039 [4.108-44.041], p < 0.001), and use of acyclovir during bortezomib treatment (OR = 3.689 [1.133-14.469], p = 0.042) were predictors of AKI. MM stages and β-2-microglobulin were not associated with increased risk of AKI. Regarding laboratory TLS, MM stage and β-2-microglobulin were higher in those with TLS than in others. In multivariate analyses, β-2-microglobulin level (OR = 1.204 [1.005-1.461], p = 0.038) and absence of high-risk chromosome abnormalities (OR = 0.143 [0.022-0.588], p = 0.016) were associated with higher risk of TLS.
CONCLUSIONS: Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors of AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app